Targeting Prostate and Breast Cancer with ODM-207: A Promising BET Inhibitor

3 June 2024
The study explores the role of BET family proteins in cancer and the potential of a new inhibitor, ODM-207, in treating prostate and breast cancer. BET proteins are known to regulate genes that promote cell growth and survival in various cancers. The research investigates ODM-207's impact on cell lines from prostate and breast cancer, demonstrating its antitumor capabilities both in the lab and in animal models.

ODM-207 was found to have a significant antiproliferative effect on multiple types of cancer cells. It was particularly effective against prostate cancer cells that express the androgen receptor, such as VCaP and 22Rv1, by reducing the expression of c-Myc without affecting the wild-type androgen receptor. In a prostate cancer model with both full-length and splice variant V7 receptors, ODM-207 showed high efficacy in tumor suppression at doses that were well tolerated, outperforming enzalutamide.

In contrast, the inhibitor's effect on the estrogen-dependent breast cancer cell line MCF-7 was different, causing tumor growth inhibition but leading to a decrease in ERα levels while c-Myc levels were already low. This indicates that the impact of BET inhibition can vary depending on the cancer type.

Furthermore, ODM-207 induced potent antiproliferative effects in patient-derived breast cancer cells, leading to cell-cycle arrest and cellular senescence.

The findings suggest that ODM-207, with its favorable pharmacological properties and demonstrated antitumor activity, could be a promising therapeutic agent for prostate and breast cancer treatment. The research was presented at the 107th Annual Meeting of the American Association for Cancer Research by Mari Björkman and colleagues.

How to Use Synapse Database to Search and Analyze Translational Medicine Data?

The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

图片包含 应用程序

描述已自动生成

Click on the image below to go directly to the Translational Medicine search interface.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成